Skip to main content

Tools and TECHNOlogies for Breakthrough in hEArt Therapies

Objective

Cardiovascular diseases including myocardial infarction (MI), which entails the irreversible loss of heart muscle tissue, constitute a major socio-economic burden in global healthcare. With whole organ transplantation as the only treatment option for end-stage heart failure, MI patients could particularly benefit from advanced cell therapies aimed at the functional reconstitution of damaged hearts. Human induced pluripotent stem cells (hiPSCs) can be derived by reprogramming patients’ somatic cells. In contrast to adult (stem) cells e.g. from blood, bone marrow or the heart, hiPSCs have unlimited expandability and differentiation potential into all relevant cell types including cardiomyocytes, endothelial cells, pericytes and connective tissue-forming cells, making them highly attractive as a universal cell source for organ repair. However, technologies for the robust therapeutic scale production of hiPSC-derived progenies in line with GMP standards and at reasonable cost are currently lacking.
TECHNOBEAT’s ultimate objectives are 1) to advance therapeutic scale cell production through innovative bioreactor technologies and novel cell monitoring tools, and 2) to develop regulatory compliant bioprocessing of innovative iPSC-based cardiac µ-tissue. The clinical translation of cardiac µ-tissue will require 3) the development and application of tools for improved cell delivery and longitudinal in vivo monitoring of cell grafts, and 4) proof-of-concept for safety and functional integration in physiologically relevant preclinical models of cellular heart repair.
Through its interdisciplinary excellence, TECHNOBEAT’s consortium of leading European stem cell researchers, clinicians, tissue-, bioprocess-, and technical- engineers in industry and academia is ideally positioned to address these ambitious objectives. It will provide new treatment options for suffering patients and increase Europe’s attractiveness as a hub for innovative medical technologies.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/clinical medicine/transplantation
  • /engineering and technology/environmental biotechnology/bioremediation/bioreactor
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

MEDIZINISCHE HOCHSCHULE HANNOVER
Address
Carl-neuberg-strasse 1
30625 Hannover
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 245 950

Participants (7)

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 649 750
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
THE UNIVERSITY OF SHEFFIELD
United Kingdom
EU contribution
€ 650 000
Address
Firth Court Western Bank
S10 2TN Sheffield
Activity type
Higher or Secondary Education Establishments
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 749 750
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
KADIMASTEM LTD
Israel
EU contribution
€ 649 950
Address
Pinchas Sapir Str 7 Weizmann Science Park
74140 Nes Ziona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG
Austria
EU contribution
€ 644 875
Address
Strubergasse 21
5020 Salzburg
Activity type
Higher or Secondary Education Establishments
DASGIP INFORMATION AND PROCESS TECHNOLOGY GMBH
Germany
EU contribution
€ 729 200
Address
Rudolf-schulten-str. 5
52428 Julich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OVIZIO IMAGING SYSTEMS
Belgium
EU contribution
€ 649 375
Address
Rue Du Bourdon 100
1180 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)